Daniel Faga (L) and Joseph Leveque (Mirati)
Weeks into CEO shakeup, Mirati bids adieu to a pair of C-suiters with KRAS drug filing around the corner
Mirati is on the cusp of emerging as the sole challenger against Amgen in the suddenly hot KRAS inhibitor market and thinks it has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
